- Home
- WNEB vs FBLG Comparison
WNEB vs FBLG Comparison
Compare WNEB & FBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- FBLG
- Stock Information
- Founded
- WNEB 1853
- FBLG 2021
- Country
- WNEB United States
- FBLG United States
- Employees
- WNEB N/A
- FBLG N/A
- Industry
- WNEB Savings Institutions
- FBLG
- Sector
- WNEB Finance
- FBLG
- Exchange
- WNEB Nasdaq
- FBLG NYSE
- Market Cap
- WNEB 165.5M
- FBLG 163.3M
- IPO Year
- WNEB N/A
- FBLG 2024
- Fundamental
- Price
- WNEB $8.71
- FBLG $2.09
- Analyst Decision
- WNEB Hold
- FBLG Strong Buy
- Analyst Count
- WNEB 4
- FBLG 1
- Target Price
- WNEB $8.50
- FBLG $16.00
- AVG Volume (30 Days)
- WNEB 33.4K
- FBLG 293.8K
- Earning Date
- WNEB 10-22-2024
- FBLG 11-02-2024
- Dividend Yield
- WNEB 3.20%
- FBLG N/A
- EPS Growth
- WNEB N/A
- FBLG N/A
- EPS
- WNEB 0.63
- FBLG N/A
- Revenue
- WNEB $74,435,000.00
- FBLG N/A
- Revenue This Year
- WNEB N/A
- FBLG N/A
- Revenue Next Year
- WNEB $5.16
- FBLG N/A
- P/E Ratio
- WNEB $13.82
- FBLG N/A
- Revenue Growth
- WNEB N/A
- FBLG N/A
- 52 Week Low
- WNEB $6.00
- FBLG $1.08
- 52 Week High
- WNEB $9.25
- FBLG $46.00
- Technical
- Relative Strength Index (RSI)
- WNEB 63.43
- FBLG N/A
- Support Level
- WNEB $8.68
- FBLG N/A
- Resistance Level
- WNEB $8.99
- FBLG N/A
- Average True Range (ATR)
- WNEB 0.21
- FBLG 0.00
- MACD
- WNEB -0.01
- FBLG 0.00
- Stochastic Oscillator
- WNEB 64.56
- FBLG 0.00
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the Company's revenues, profits, and assets are derived by the Bank from banking products and services.
About FBLG FIBROBIOLOGICS INC
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.